Phaco (Phacoemulsification) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Phacoemulsification (phaco) is the dominant surgical technique for cataract removal worldwide, accounting for over 90% of the approximately 19 million cataract operations performed annually across high- and middle-income countries. The procedure uses high-frequency ultrasound energy (28,000–40,000 cycles per second) delivered through a titanium hollow needle to emulsify (break apart and aspirate) the crystalline lens, followed by implantation of a foldable intraocular lens (IOL) through a self-sealing incision of 2.2–2.8 mm.

The procedure was invented by Dr. Charles D. Kelman in New York in 1967, inspired by an ultrasonic dental scaling tool — a paradigm shift from the large (10–12 mm) extracapsular cataract extraction (ECCE) incisions that had been standard for decades. Kelman's original machine operated at 40 kHz with primitive fluidics. Modern phaco platforms (Alcon Centurion, Johnson & Johnson Veritas, Zeiss Callisto) have transformed the procedure into a precision microsurgical operation with real-time IOP compensation, automated fluidic sensing, and longitudinal or torsional ultrasound delivery.

The OZil torsional handpiece (Alcon, introduced 2006) delivers rotary ultrasound motion at the phaco tip, reducing repulsion of lens fragments, generating less heat at the incision, and causing less endothelial cell loss than traditional longitudinal (push-pull) ultrasound — important for dense brunescent cataracts in elderly patients with already-compromised corneal endothelium.

The basic surgical steps are: corneal incision → capsulorhexis (circular tear in anterior capsule, 5–5.5 mm) → hydrodissection and hydrodelineation → nuclear emulsification → cortical aspiration → IOL implantation in the bag → wound hydration. The entire procedure takes 10–25 minutes for a routine case.

Phacoemulsification is the definitive treatment for all clinically significant cataracts:

• Age-related nuclear sclerotic cataract: The most common type. Progressive yellowing and hardening of the lens nucleus, graded on the LOCS III or Oxford Cataract Classification scales. Surgery is indicated when the patient's visual acuity or functional quality of life is impaired — typically BCVA <6/9 with spectacle correction, or glare-disability on contrast sensitivity testing.
• Cortical cataract: Spoke-like opacities in the lens cortex that progress centripetally. Associated with ultraviolet-B exposure and diabetes. May cause polyopia and glare earlier than nuclear cataracts despite relatively preserved central VA.
• Posterior subcapsular cataract (PSC): Most visually disabling at an early stage — located directly at the posterior nodal point. Disproportionate impact on reading and bright-light conditions. Associated with corticosteroid use, diabetes, and myopia. Often requires earlier surgical intervention than nuclear cataracts.
• Traumatic cataract: Following blunt or penetrating ocular trauma. May present acutely (intumescent, swollen) or subacutely. Often associated with zonular damage, vitreous prolapse, or iris injury, requiring modified surgical planning.
• Congenital and paediatric cataract: Requires urgent surgery in visually significant cases to prevent amblyopia. Paediatric phaco uses modified technique — posterior capsulotomy and anterior vitrectomy are routinely performed, and optical rehabilitation with aphakic glasses or contact lenses (or IOL for children >2 years) follows.
• Refractive lens exchange (RLE): Elective phaco of a clear lens to correct high myopia (>−8 D), high hyperopia (>+4 D), or presbyopia — particularly in patients over 50 who are poor LASIK candidates.

Comprehensive pre-operative assessment is mandatory for safe phacoemulsification. Key evaluations include:

• Visual acuity and refraction: BCVA, manifest refraction, glare testing with a brightness acuity tester (BAT). Surgery threshold is typically BCVA <6/9, or functional impairment (night driving, reading difficulty) regardless of Snellen acuity.
• Optical biometry: IOL power calculation using optical biometry (Zeiss IOLMaster 700, Haag-Streit Lenstar). AL, K readings, ACD, WTW, and white-to-white measurements inform advanced IOL power formulas (Barrett Universal II, Kane formula, Hill-RBF) for target emmetropia. Axial length outliers (high myopes >26 mm, nanophthalmos <21 mm) require specialised formula selection.
• Corneal endothelial cell count (specular microscopy): Pre-operative ECC <1,000 cells/mm² (Fuchs dystrophy, prior trauma) represents elevated risk for corneal decompensation post-phaco. Surgeons use minimal ultrasound energy, dispersive viscoelastic protection, and may plan simultaneous DMEK if decompensation is likely.
• Fundus assessment: Dilated fundoscopy or OCT to exclude concurrent macular pathology that would limit visual prognosis. Essential for managing expectations in AMD, diabetic retinopathy, epiretinal membrane, or glaucomatous damage.
• Systemic considerations: Alpha-1 antagonists (tamsulosin/Flomax — IFIS risk), anticoagulation management, diabetes (HbA1c, macular stability), and fitness for topical anaesthesia. Warfarin/DOAC need not be stopped for topical phaco.

Patients with very dense brunescent nuclei (LOCS III NO5-NO6), small pupils, shallow anterior chambers, or pseudoexfoliation syndrome require specific surgical planning and experienced surgeons.

Modern phacoemulsification encompasses several technique variations that experienced surgeons select based on nuclear density, anterior chamber depth, and equipment available:

• Divide-and-conquer (Shepherd technique): Four deep grooves are created in the nucleus at 90-degree intervals, then the quadrants are cracked and aspirated sequentially. Useful for moderate nuclear densities. Uses more ultrasound energy than chopping techniques.
• Stop-and-chop (Koch technique): A single deep groove is made, the nucleus is divided into two halves, then each half is chopped into smaller fragments using a second instrument. More efficient for denser nuclei.
• Phaco-chop (Nagahara technique): A sharp phaco chopper is inserted beneath the phaco tip, hooking the nucleus equator and chopping towards the tip. Zero or minimal ultrasound during chopping — most energy-efficient technique. Preferred for dense brunescent cataracts as it minimises thermal and mechanical stress on zonules and endothelium.
• Torsional ultrasound (OZil, Alcon): The phaco tip oscillates rotationally (±4 degrees) at 32 kHz. Compared with longitudinal US, torsional phaco reduces repulsion, incision burn risk, and cumulative dissipated energy (CDE) — particularly beneficial for dense nuclei.
• Fluidics management: The phaco machine maintains anterior chamber stability via a balance between irrigation (bottle height or peristaltic pressure) and aspiration (flow rate 20–45 cc/min, vacuum 100–600 mmHg). Active fluidics systems (Centurion Adaptive Fluidics) automatically compensate for surge — the sudden deepening of the AC when a large fragment occludes the tip and is suddenly aspirated. Proper fluidics prevent posterior capsule rupture (PCR).
• Femtosecond laser-assisted cataract surgery (FLACS): A femtosecond laser (LenSx, Catalys, Victus) performs the capsulorhexis, nuclear pre-fragmentation, and corneal incisions before the phaco handpiece is introduced. Produces a more reproducible circular capsulorhexis and reduces phaco energy required. Meta-analyses show modest reductions in CDE but similar BCVA outcomes vs. manual phaco; higher cost limits routine adoption.

Phacoemulsification has a well-established, decades-long safety and efficacy record:

• Small incision (<3 mm): Self-sealing clear corneal incisions require no sutures in routine cases. This dramatically reduces surgically-induced astigmatism (SIA typically <0.3 D with modern technique) and accelerates wound healing compared with ECCE (10–12 mm sutured incision, SIA 1–2 D).
• Topical anaesthesia: No periocular injection (no retrobulbar/peribulbar block) is needed for routine cases. Topical tetracaine or lignocaine drops, supplemented with intracameral 1% unpreserved lignocaine, provide excellent anaesthesia with no risk of retrobulbar haemorrhage, globe perforation, or optic nerve injury.
• Rapid visual rehabilitation: Most patients achieve driving-standard vision within 24–48 hours. Return to non-strenuous work is typically possible within 1–3 days.
• High BCVA outcomes: Over 95% of eyes without pre-existing ocular pathology achieve BCVA of 6/12 or better. Approximately 85% achieve 6/6 or better with spectacle correction, and 75% achieve 6/6 uncorrected (emmetropic target).
• Bilateral same-day surgery (ISBCS): Immediate sequential bilateral cataract surgery — both eyes on the same day — is increasingly offered in high-volume cataract programmes. Cochrane reviews show no increased risk of bilateral endophthalmitis versus standard delayed DSBCS when strict aseptic protocols are followed.
• Universal applicability: Phaco can be performed under topical anaesthesia as a daycase in 15–25 minutes for routine cases, making it the world's most commonly performed elective surgical procedure.

While phacoemulsification has an excellent safety profile, surgeons and patients should be aware of the following complications:

• Posterior capsule rupture (PCR): The most feared intraoperative complication, occurring in 1–2% of cases in experienced hands, rising to 3–6% for high-complexity cases (hard nuclei, small pupils, pseudoexfoliation). PCR allows vitreous prolapse into the anterior segment, requiring careful anterior vitrectomy. If the capsulorhexis remains intact, sulcus IOL fixation may still be possible; severe PCR requires anterior chamber IOL or scleral-fixated IOL.
• Dropped nucleus: Complete or partial displacement of nuclear fragments into the vitreous cavity through the PCR. Requires posterior segment intervention (pars plana vitrectomy) by a vitreoretinal surgeon. Risk of retinal detachment, cystoid macular oedema (CME), and raised IOP.
• Endophthalmitis: Intraocular infection. Incidence of 0.02–0.05% with prophylactic intracameral cefuroxime (0.1 mL of 1 mg/0.1 mL). The ESCRS Endophthalmitis Study (2007) demonstrated a 4.9-fold reduction in endophthalmitis with intracameral cefuroxime vs. subconjunctival antibiotics alone.
• Cystoid macular oedema (Irvine-Gass syndrome): Subclinical CME on OCT occurs in up to 20–30% of post-phaco eyes; clinically significant CME (visually symptomatic) in 1–2%. Treated with topical NSAIDs ± steroids. Risk increased in diabetics, uveitis patients, and post-PCR cases.
• Corneal decompensation (bullous keratopathy): Permanent corneal oedema due to excessive ultrasound energy or pre-existing Fuchs endothelial dystrophy. Requires Descemet membrane endothelial keratoplasty (DMEK) or penetrating keratoplasty for vision restoration.
• IOL dislocation: Late spontaneous dislocation (years post-surgery) of in-the-bag IOL-capsular complex, particularly in pseudoexfoliation or high myopia. Incidence 0.1–2% over 10 years. Requires IOL repositioning or exchange.

Standardised post-operative care protocols are essential for optimising outcomes after phacoemulsification:

• Day 1 review: All phaco patients are seen the following day. Assessment includes UCVA and BCVA, IOP (steroid-induced IOP spike is common — up to 15–20% transient), anterior segment review (wound integrity, anterior chamber depth, corneal clarity, IOL position), and patient-reported pain or vision concerns.
• Week 1 (5–7 days): Second formal post-operative visit. IOP recheck, refraction, slit-lamp assessment. Patients with IOP >25 mmHg receive IOP-lowering drops and early steroid taper.
• 4–6 weeks: Final refraction and spectacle prescription if required. Assess for posterior capsule clarity. Confirm absence of CME on OCT if visual recovery is below expectation.
• YAG capsulotomy: Indicated if PCO causes visual symptoms (typically BCVA <6/9 attributable to capsule haze). Performed in-office with Nd:YAG laser (5 minutes, no incision). Success rate 100%; visual improvement immediate. Performed 3 months to 5 years post-phaco in 10–30% of patients.

Standard post-operative medications: topical antibiotic (moxifloxacin 0.5%, 4× daily for 2 weeks), topical NSAID (ketorolac or nepafenac, 4× daily for 4–6 weeks), topical prednisolone acetate 1% tapering over 4 weeks (start 4× daily, reduce weekly). Patients are advised to avoid eye rubbing, swimming (4 weeks), and heavy lifting (>10 kg) for 1 week.

Phacoemulsification is one of the most cost-effective surgical interventions in medicine, with cost-per-QALY ratios comparable to coronary artery bypass grafting and hip replacement:

• NHS (United Kingdom): Standard phaco with monofocal IOL is fully funded by the NHS. The Cataract NICE guideline (NG77, 2023) mandates surgery when cataract causes visual impairment — waiting lists are typically 6–18 months in the current NHS backlog. Premium IOL upgrades (multifocal, toric) are patient-funded.
• USA (Medicare): Medicare Part B covers phaco with standard monofocal IOL. The facility and professional fees total approximately USD 1,500–2,500 (Medicare reimbursement rate). Premium IOL and FLACS add-ons are patient-funded (USD 1,500–4,000 extra per eye).
• Private/self-pay UK: Bilateral standard phaco: £3,000–£5,000. Bilateral with toric IOL: £4,000–£6,500. Premium multifocal: £5,500–£8,500.
• India (medical tourism): Phaco with monofocal IOL at NABH/JCI-accredited centres: USD 400–800 per eye. With PanOptix trifocal IOL: USD 1,000–1,800 per eye. India performs over 6.5 million cataract surgeries annually and has among the world's highest volume surgeon expertise.
• FLACS premium: Femtosecond laser-assisted surgery adds USD 500–1,500 per eye to conventional phaco costs. Clinical evidence does not strongly support superior visual outcomes over expertly performed manual phaco; decision should be individualised.

The Vision Loss Expert Group estimates that approximately 45 million people globally are blind from cataract — 94% in low- and middle-income countries. High-volume SICS (small incision cataract surgery) and phaco programmes in India, Nepal, and sub-Saharan Africa represent vital public health interventions.

While phacoemulsification is the dominant technique, several alternatives exist for specific clinical situations:

• Small incision cataract surgery (SICS / manual MSICS): A 6–7 mm scleral tunnel incision allows nuclear delivery without phaco energy. No expensive phaco machine required. Used extensively in high-volume low-resource settings (India, Nepal, Africa). Visual outcomes at 6 weeks are equivalent to phaco; 6-month astigmatism is slightly higher. Cost-effective in volume cataract programmes.
• Extracapsular cataract extraction (ECCE): A 10–12 mm superior limbal incision with a sutured wound closure. Now reserved for very hard brunescent nuclei (LOCS III NO6) where phaco energy would be excessive, or in settings where phaco machines are unavailable. Longer recovery (6–8 weeks), higher SIA.
• Femtosecond laser-assisted cataract surgery (FLACS): A pre-phaco femtosecond laser step that performs the capsulorhexis, nuclear pre-softening, and corneal incisions. Higher reproducibility of capsulorhexis diameter. Evidence for superior clinical outcomes vs. expert manual phaco remains inconclusive — FLACS remains an adjunct to, not a replacement for, phacoemulsification.
• Intumescent white cataract — manual technique: Very mature white cataracts with liquefied cortex require modified capsulorhexis technique (trypan blue staining, controlled decompression of intumescent cortex) to prevent Argentinian flag sign. Phaco remains feasible with appropriate precautions.
• Watchful waiting: If the cataract is not visually significant and the patient is asymptomatic, observation with serial visual acuity monitoring is appropriate. Dietary antioxidants have not been proven to slow cataract progression in clinical trials.